Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis

• Status: Completed
• Trial end date: 2019-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the effect of repeated low-dose erythropoietin (EPO) treatment on necrotizing enterocolitis (NEC) in very preterm infants. Half of participants will receive EPO, while the other half will receive a placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhengzhou University
• Collaborators: Göteborg University; The First Affiliated Hospital of Zhengzhou University; Women and Children Health Care Center of Luoyang, China; Zhengzhou Children's Hospital, China
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Preterm infants with gestation age ≤ 32weeks

• Within 72 hours after birth

• Written informed consent obtained from parents

Exclusion Criteria:

• Genetic or metabolic diseases

• Congenital abnormalities

• Polycythemia

• Intracranial hemorrhage grade III/IV

• Unstable vital signs (such as respiration and circulation failure)